期刊文献+

静脉水化联合前列地尔对冠状动脉介入术后对比剂肾病的预防作用 被引量:6

Inhibitory Effect of Intravenous Hydration Combined with Alprostadil on Contrast-induced Nephropathy in Patients with Percutaneous Coronary Intervention
原文传递
导出
摘要 目的:观察静脉水化联合前列地尔对冠状动脉介入(PCI)术后对比剂肾病(CIN)的预防作用。方法:选择行PCI术的患者80例,随机分为对照组38例(常规静脉水化)和试验组42例(常规静脉水化联合前列地尔)。观察两组患者PCI术前和术后24、48、72h及7d时的血清肌酐(Scr)、血尿素氮(BUN)、尿β2-微球蛋白(β2-mG),比较两组患者CIN的发生率,记录不良反应发生情况。结果:两组患者术后24hScr、BUN、尿β2-mG比较差异均无统计学意义(P>0.05);试验组术后48、72h及7d时的Scr、BUN、尿β2-mG下降较对照组同期更为显著,差异有统计学意义(P<0.05或P<0.01)。对照组CIN发生率(5例,13.1%)显著高于试验组(3例,7.1%),差异有统计学意义(P<0.05)。两组患者均未见不良反应发生。结论:接受PCI术的患者,在常规静脉水化基础上加用前列地尔可显著降低CIN的发生率,且安全性较好。 OBJECTIVE:To investigate the inhibitory effect of intravenous hydration combined with alprostadil on contrast-induced nephropathy(CIN) in patients underwent percutaneous coronary intervention(PCI).METHODS:80 patients underwent PCI were randomized into control group(38 cases,conventional intravenous hydration) and trial group(42 cases,conventional intravenous hydration+alprostadil).The levels of Scr,BUN and urinary β2-microglobulin(β2-mG) were compared between 2 groups before PCI and 24 h,48 h,72 h and 7 d after PCI.The incidence of CIN was also compared.RESULTS:There was no significant difference in SCr,BUN and urinary β2-mG level between 2 groups 24 h after operation(P0.05);the decrease of Scr,BUN and urinary β2-mG levels in experimental group were more significant than in control group 48 h,72 h and 7 d after operation,there was statistical significance(P0.05 or P0.01);there were 5 cases of CIN(13.1%) in control group,while 3 cases(7.1%) in experiment group,there was statistical significance(P0.05).CONCLUSIONS:Intravenous hydration is main measure to prevent the occurrence of CIN in patients underwent PCI.Intravenous hydration combined with alprostadil could obviously reduce the incidence of CIN.
出处 《中国药房》 CAS CSCD 2013年第20期1870-1872,共3页 China Pharmacy
关键词 冠状动脉疾病 对比剂肾病 静脉水化 前列地尔 Coronary artery disease Contrast-induced nephropathy Intravenous hydration Alprostadil
  • 相关文献

参考文献19

  • 1Nash K,Hafeez A, Hou S. Hospital-acquired renal insuf-ficiency[J]. Am J Kidney Dis, 2002,39(5) : 930.
  • 2Thomsen HS. How to avoid CIN : guidelines from the Eu-ropean Society of Urogenital Radiology [J]. Nephrol DialTransplant,2005,20(Suppl 1):i18.
  • 3Trivedi HS,Moore H, Nasr S,et al. A randomized pros-pective trial to assess the role of saline hydration on thedevelopment of contrast nephrotoxicity [J]. Nephron ClinPract,2003,93(1):C29.
  • 4Chronopoulos A, Rosner MH,Qruz DN, et al. Acute kid-ney injury in the elderly : a review[J]. Contrib Nephrol,2010,165:315.
  • 5Rihal CS,Textor SC,Grill DE,et al. Incidence and prog-nostic importance of acute renal failure after percutaneouscoronary intervention!^]. Circulation, 2002,105 (19):2 259.
  • 6Maeder M,Klein M, Fehr T,et al. Contrast nephropa-thy :review focusing on prevention[J]. J Am Coll Cardiol,2004,44(9):1 763.
  • 7田间,孙福成.对比剂肾病的研究现状[J].山东医药,2012,52(24):92-94. 被引量:5
  • 8Tumlin J, Stacul F,Adam A, et al. Pathophysiology ofcontrast-induced nephropathy [J]. Am J Cardiol, 2006,98(6A):14K.
  • 9陈永利,杨世诚,付乃宽.经皮冠状动脉成形术后对比剂肾病的研究进展[J].山东医药,2012,52(8):97-99. 被引量:14
  • 10Toprak O. Risk markers for contrast-induced nephropathy[J]. Am J Med Sci, 2007,334(4):283.

二级参考文献45

  • 1熊晓玲,贾汝汉,杨定平,丁国华.依贝沙坦抑制造影剂诱导的肾小管上皮细胞凋亡[J].中华肾脏病杂志,2006,22(11):682-687. 被引量:16
  • 2Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention[J]. Am J Cardiol, 2009,101(12) : 1 657.
  • 3Amini M, Salarifar M, Amirbaigloo A, et al. N-acetylaysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial[J]. Trials, 2009,10:45.
  • 4Ray KK, Cannon CP, Ganz E Beyond lipid lowering what have we learned about the benefits of statins from the acute coronary syndromes trials? [J]. Am J Cardiol, 2006, 98(11A) : 18.
  • 5Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events[J]. Drugs, 2007,67(Suppl 1) :29.
  • 6Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy[J]. Kidney Int, 2005,68 (1):14.
  • 7Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial unction in coronary bypass surgery[J]. Eur J Cardiothorac Surg, 2005,28 (6) : 805.
  • 8Melfi R, Nusca A, Patti G, et al. Statins and their role in pre-percutaneous coronary intervention[J]. Curr Cardiol Rep, 2010,12(4):295.
  • 9Nusca A, Melfi R, Patti G, et al. Statin loading before percutaneous coronary interve-ntion: proposed mechanisms and applications[J]. Future Cardiol, 2010, 6 (5) : 579.
  • 10Wallace SM, Maki-Petaja KM, Cheriyan J, et al. Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction[J]. Br Clin Pharmacol, 2010, 70 (6):799.

共引文献21

同被引文献68

  • 1徐红,陈丽萌,李学旺.肾功能不全患者发生造影剂肾病的危险因素和预后[J].中国医学科学院学报,2005,27(2):232-236. 被引量:29
  • 2汪斌,刘志忠,张丰富.冠状动脉介入诊治中高敏C反应蛋白与造影剂肾病的相关性分析[J].中国医药,2007,2(8):457-459. 被引量:35
  • 3Charytan DM,Wallentin L,Lagerqvist B,et al.Early angiography in patients with chronic kidney disease:a collaborative systematic review[J].Clin J Am Soc Nephrol,2009,4(6):1032-1043.
  • 4Gruberg L,Mehran R,Dangas G,et al.Acute renal failure requiring dialysis after percutaneous coronary interventions[J].Catheter Cardiovasc Interv,2001(52):409-416.
  • 5Rich MW,Crecelius CA.Incidence,risk factors,and clinical course of acute renal insufficiency after cardiac catheterization in patients70 years of age or older.A prospective study[J].Arch Intern Med,1990,150(6):1237-1242.
  • 6Merten GJ,Burgess WP,Gray LV,et al.Prevention of contrast induced nephropathy with sodium bicarbonate[J].JAMA,2004,291(19):2328-2334.
  • 7Adolph E,Holdt-Lehmann B,Chatterjee T,et al.Renal insufficiency following radiocontrast exposure trial(REINFORCE):a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast induced nephropathy,coronary artery disease[J].Coron Artery Dis,2008,19(6):413-419.
  • 8中华医学会心血管病学会分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南:2012[J].中华危重症医学杂志,2012,5(3):169-180.
  • 9Briguori C,Manganelli F,Scarpato P,et al.Acetylcysteine and contrast agent-associated nephrotoxicity[J].J Am Coll Cardiol,2002,40(2):298-303.
  • 10Marenzi G,Larri G,Campodonico J,et al.Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients[J].Am J Med,2006,119(2):155-162.

引证文献6

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部